Compare AbbVie Inc (ABBV) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs National Beverage Corp. — how do they compare? AbbVie Inc trades at $253.18 (market cap $449.91B), while National Beverage Corp. trades at $32.93 (market cap $3.04B). The key difference: AbbVie Inc is far larger — about 148× National Beverage Corp.'s market cap, and AbbVie Inc pays a 2.72% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| ABBV | FIZZ | |
|---|---|---|
Market Cap | $449.91B | $3.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $47.69 |
52-Week Low | $184.85 | $31.00 |
Enterprise Value | $513.38B | $2.75B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
FIZZ (National Beverage Corp.) trades at $32.48, down 2.55% today, with a bearish technical signal and mixed earnings performance. The company maintains strong profitability with 15.56% net margin and 34.03% ROE, though revenue has stagnated around $1.2B annually. Recent news highlights a special $3.25 dividend announcement that boosted shares despite three consecutive quarterly earnings misses.
Outlook remains cautious with 50% of analysts rating Sell amid competitive pressures and consumer weakness. The dividend provides shareholder return but earnings consistency remains a concern. Key risks include tariff impacts and market saturation, while current valuation multiples appear reasonable given profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
